Clinical Trials Resource Center

New Medical Therapies™


Patient Medical Areas

June 9, 2014

Jazz Pharmaceuticals issued results of a phase IIb study of JZP-110 (formerly known as ADX-N05) for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. This phase IIb, double-blind, placebo- controlled, parallel-group, multicenter study evaluated the safety and efficacy of JZP-110 over 12 weeks in 93 subjects aged 18 to 70 years with an ICSD-2 diagnosis of narcolepsy. Subjects were randomized to once-daily placebo (n=49) or JZP-110 (n=44). JZP-110 was administered at a dose of 150mg/day during weeks one through four and at a dose of 300mg/day during weeks five through 12. Sleep Onset Latency on the Maintenance of Wakefulness Test showed improvement on the time to fall asleep for subjects receiving JZP-110 150mg of 9.5 minutes v. placebo in 1.4 minutes (N=40 v. N=45, respectively; p<0.0001). On the Clinical Global Impression- Change scale, symptoms were “much improved” or “very much improved,” with JZP-110 150mg showing an 80% improvement v. placebo at 51% (N=43v. N=47, respectively; p<0.0066). JZP-110 150mg also showed a decrease in overall sleepiness as measured by the Epworth Sleepiness Scale. JZP-110 150mg showed a -5.6 point change (N=43) compared to placebo of -2.4 points (N=47) for a statistically significant difference of p=0.0038. Jazz Pharmaceuticals plans to evaluate JZP-110 in phase III clinical studies in patients with EDS associated with narcolepsy and in patients with EDS associated with obstructive sleep apnea.

February 14, 2005

Axonyx announced top-line results of their first phase III trial of phenserine, their acetylcholinesterase inhibitor under investigation for the treatment of mild-to-moderate Alzheimer’s disease (AD). Trial data indicated that the neither trial dose of the drug met the primary endpoint, improvement in score on the ADAS-cog and CIBIC diagnostic scales, vs. placebo after 26 weeks of treatment. Non-significant trends towards improvement were noted in both metrics at both dose regimens, and no serious safety or tolerability concerns were raised. This double-blind, placebo-controlled study enrolled 384 subjects across 16 sites in Spain, the United Kingdom, Croatia, and Austria. Subjects were randomized to receive one of two doses of phenserine (10mg or 15mg) or placebo twice daily for 6 months. Axonyx announced that the planned interim analysis of their ongoing phase II b trials of the drug, investigating phenserine’s ability to lower levels of beta-amyloid precursor protein and beta-amyloid in the plasma and cerebrospinal fluid (CSF), would not be affected by these results.

Cephalon has reported positive combined results from four phase III trials of Nuvigil (armodafinil) for the treatment of excessive sleepiness associated with narcolepsy (1 study), shift work sleep disorder (1 study) or obstructive sleep apnea/hypopnea syndrome (2 studies). Compiled data demonstrated significant efficacy in improving measures of objective sleep latency, including the Maintenance of Wakefulness Test and the Multiple Sleep Latency Test, and in the physician rating of Clinical Global Impression-Change, vs. placebo (p<0.05). The drug was also shown to promote wakefulness late in the day when administered in the morning, confirming a long duration of action. All 4 trials were 12-week, double-blind, randomized, placebo-controlled studies, which enrolled a combined total of roughly 1,000 patients. Subjects received one of two doses of the drug (150 or 250 mg) or placebo once daily. Cephalon announced that these results were in line with their intention to submit and NDA for the drug before the end of Q1 2005.

Repligen announced preliminary results of a phase II trial of secretin, for the treatment of refractory schizophrenia. Data from the study yielded no significant improvements in symptom severity scores on either the Clinical Global Impression (CGI) or the Positive And Negative Syndrome Scale (PANSS), which were assessed at baseline and 6 times during the study. Responders on the CGI scale were noted in both the low dose (n=3, 20% response rate) and high dose (n=4, 29% response rate) secretin group and in the placebo group (n=2, 13% response rate), but the difference between these rates was also non-significant, possibly due to the small cohort size. A non-significant trend towards improvement was seen in a sub-section analysis of the PANSS dysphoric mood scale (anxiety, tension, etc.) in the secretin group (p=0.06), and several clinical investigators were reported to have noted transient changes in the social interaction at the time of the treatment, though these responses were not quantified. This double-blind trial enrolled 44 subjects, who received one of two doses of secretin (2 CU/kg, n=15; or 5 CU/kg, n=14) or placebo (n=15) in 4 intravenous doses over 2 weeks. The company announced that they were preparing a follow-up study to statistically measure the transient changes in mood noted by investigators.

September 20, 2004

Orphan Medical has announced the results of a phase III b study of Xyrem, for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy; Xyrem is currently approved for the treatment of cataplexy, another common symptom of narcolepsy. The study found that the study met its primary endpoint of improving wakefulness and alertness, with a significant improvement over placebo in objective wakefulness score, as measured on a standardized scale. Furthermore, the study also met its secondary endpoint of significantly reducing sleepiness score on another, similar objective standardized scale, compared with placebo. The study also found that while Xyrem was effective alone in limiting EDS, co-administration of Provigil (an approved EDS treatment) yielded greater efficacy than either agent alone. The multi-center, double-blind, placebo-controlled, parallel-group study randomized subjects with established EDS into one of four treatment arms for two weeks: Xyrem alone, Provigil alone, Xyrem and Provigil, or placebo. Orphan Medical announced plans to submit an sNDA for Xyrem for the treatment of EDS.

June 1, 2004

Orphan Medical reported positive results from a phase IIIb trial investigating Xyrem (sodium oxybate) for the treatment of narcolepsy. Results showed the study demonstrated a statistically significant change in the Epworth Sleepiness Score and Clinical Global Impressions of Change, the study’s primary endpoint measures. The double-blind, placebo-controlled, randomized study, called SXB-15, enrolled 228 subjects for eight weeks at 48 sites in North America and Europe. The study was designed to assess the improvement in the excessive daytime sleepiness of patients with narcolepsy. Subjects were administered Xyrem (4.5, 6.0 or 9.0 grams plus stimulant therapy. Secondary endpoints included changes in the Maintenance of Wakefulness Test (MWT), polysomnography recordings, as well as reductions in inadvertent daytime naps, nighttime awakenings and the number of cataplexy attacks. Additional data will be presented at the Associated Professional Sleep Societies meeting in Philadelphia in June 2004.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.